Inhibition of striatal dopamine release by the L-type calcium channel inhibitor isradipine co-varies with risk factors for Parkinson’s
BRIMBLECOMBE K., CONNOR-ROBSON N., BATAILLE C., ROBERTS B., Gracie C., O'Connor B., te Wade Naude R., Karthik G., RUSSELL A., WADE-MARTINS R., CRAGG S.